Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.
Shanghai Henlius Biotech reported a 16.5% rise in total revenue to RMB6.67 billion in 2025, driven mainly by product sales and R&D services, while total profit edged up to RMB827 million despite a sharp increase in R&D expenditure to RMB2.49 billion as the company accelerated innovation projects. The board opted not to declare a final dividend for the year, underscoring a capital allocation focus on research, clinical expansion and international growth rather than near-term cash returns to shareholders.
Operationally, Henlius continued to deepen its global presence, with 10 products approved across 40 indications in major markets such as China, the United States and Europe, and broader coverage in Asia-Pacific and Latin America. Its PD-1 antibody HANSIZHUANG (Hetronifly in Europe) secured EU approval for extensive-stage small cell lung cancer and additional indications in several Asian markets, while HLX14 became the first China-developed denosumab to win approvals in the United States, Europe and the United Kingdom under the BILDYOS and BILPREVDA brands, strengthening the company’s competitive positioning in oncology and osteoporosis therapies worldwide.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$64.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company specializing in the development, manufacture and commercialization of biologic drugs, including innovative monoclonal antibodies and biosimilars. Its products target oncology and other serious diseases, with an expanding global footprint across roughly 60 countries and regions, serving over one million patients worldwide.
Average Trading Volume: 962,682
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$23.64B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.